Treatment for malignant primary brain tumors, including glioblastoma, remains a significant challenge despite advances in therapy. CAR-T cell immunotherapy represents a promising alternative to conventional treatments. This review discusses the landscape of clinical trials for CAR-T cell therapy targeting ...
Brian Hill, MD, PhD:The long-term treatment outcomes for patients treated with CAR T [chimeric antigen-receptor T-cell] therapy are very impressive in the sense that historically we knew that these patients really had very limited overall survival. What we can see in some of the long-term ...
When Can I Get CAR T-Cell Therapy? DID YOU KNOW? In the United States right now, there are many ongoing or planned clinical trials focused on CAR T-cell therapy for DLBCL. Visit clinicaltrials.gov to find a trial in your area.
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR T cells is ...
以CAR-T疗法为代表的细胞免疫疗法的出现,为肿瘤患者带来了新的希望,得益于CAR-T疗法,让很多难治性、复发性血液系统恶性肿瘤获得了持续缓解,甚至存在“临床治愈”的希望。 截至2023年,ClinicalTrials.gov数据显示,全球免疫细胞治疗的临床研究...
In recent decades, the advent of immune-based therapies, most notably Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of numerous studies indicate that CAR-T cell therapy has had a remarkable abil
The CAR T-Cell Therapy market reached a value of US$ 3,589.7 Million in 2023 to reach US$ 11,282.5 Million by 2034 at a CAGR of 10.85% during 2024-2034.
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are sti
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (...